We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Point-of-Care Hemoglobin Testing Compared with Laboratory Analyzer

By LabMedica International staff writers
Posted on 28 Jan 2014
Hemoglobin concentration is assessed to detect anemia and its associated morbidities and is usually determined from venous or capillary blood samples run on a laboratory analyzer.

The blood sample method requires a needle stick and results can be delayed, and exposes caregivers to risks associated with needle sticks and blood exposure. More...
Noninvasive hemoglobin determination would be of benefit to patients and caregivers because it would allow for quick and painless point-of-care assessment.

Clinical scientists at Long Beach Veterans Administration Healthcare System (CA, USA) enrolled 474 subjects in a study to compare a noninvasive hemoglobin concentration measurement method with the traditional technique. A noninvasive hemoglobin (SpHb) test device was placed on the subject's nondominant ring finger. The sensor was covered with an opaque shield to prevent optical interference. A noninvasive hemoglobin measurement was obtained from each subject. Perfusion index, finger temperature, and oxygen saturation (SpO2), measured by the noninvasive hemoglobin test device, were also recorded.

Immediately following the noninvasive testing, a venous blood sample was obtained and analyzed for reference hemoglobin value (Hb) with a laboratory hematology analyzer (LH 500, Beckman Coulter; Brea, CA, USA). A capillary blood sample was also obtained by finger stick within 15 minutes of the noninvasive reading and the venous sample and analyzed immediately with a HemoCue 201 point-of-care hemoglobinometer (Cypress, CA, USA). The noninvasive hemoglobin (SpHb) test device was the Pronto-7, version 2.19, with a rainbow 4D sensor, rev E, (Masimo Corp., Irvine, CA, USA).

The reference hemoglobin concentration ranged from 8.6 g/dL to 17.4 g/dL. Analysis of data from all subjects showed a bias ± standard deviation of −0.1 ± 1.1 g/dL for Pronto-7 SpHb and −0.1 ± 1.6 g/dL for HemoCue, compared with the hematology analyzer. SpHb could be used to safety screen between 73% and 95% of the population to rule out anemia, with SpHb values of ≥11.5g/dL to 13 g/dL and an additional 0.5% of the population to rule in anemia, with SpHb values of 7.5g/dL to ≤10 g/dL.

The authors concluded that their study shows noninvasive hemoglobin measurement with SpHb offers similar accuracy as another established point-of-care method, HemoCue, in an outpatient clinic environment. Its noninvasive and quick testing characteristics may translate into added benefits to patient care. The study was published on January 13, 2014, in the International Journal of Laboratory Hematology.

Related Links:

Long Beach Veterans Administration Healthcare System
Beckman Coulter
Masimo Corp.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automatic CLIA Analyzer
Shine i6000
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.